WO1991007184A1 - SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP and H2O¿2? - Google Patents

SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP and H2O¿2? Download PDF

Info

Publication number
WO1991007184A1
WO1991007184A1 PCT/US1990/005846 US9005846W WO9107184A1 WO 1991007184 A1 WO1991007184 A1 WO 1991007184A1 US 9005846 W US9005846 W US 9005846W WO 9107184 A1 WO9107184 A1 WO 9107184A1
Authority
WO
WIPO (PCT)
Prior art keywords
pvp
complex
anhydrous
water
formulation
Prior art date
Application number
PCT/US1990/005846
Other languages
French (fr)
Inventor
John J. Merianos
Herbert A. Lieberman
Robert B. Login
Paul Garelick
Original Assignee
Gaf Chemicals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/434,943 external-priority patent/US5008093A/en
Priority claimed from US07/450,695 external-priority patent/US5008106A/en
Priority claimed from US07/533,749 external-priority patent/US5066488A/en
Application filed by Gaf Chemicals Corporation filed Critical Gaf Chemicals Corporation
Publication of WO1991007184A1 publication Critical patent/WO1991007184A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22Peroxides; Oxygen; Ozone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/817Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
    • A61K8/8176Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/12Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
    • A61L12/124Hydrogen peroxide; Peroxy compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/24Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B15/00Peroxides; Peroxyhydrates; Peroxyacids or salts thereof; Superoxides; Ozonides
    • C01B15/01Hydrogen peroxide
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00Treatment of water, waste water, or sewage
    • C02F1/72Treatment of water, waste water, or sewage by oxidation
    • C02F1/722Oxidation by peroxides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/18Oxygen-containing compounds, e.g. metal carbonyls
    • C08K3/20Oxides; Hydroxides
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0047Detergents in the form of bars or tablets
    • C11D17/0065Solid detergents containing builders
    • C11D17/0073Tablets
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0047Detergents in the form of bars or tablets
    • C11D17/0065Solid detergents containing builders
    • C11D17/0073Tablets
    • C11D17/0086Laundry tablets
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/39Organic or inorganic per-compounds
    • C11D3/3902Organic or inorganic per-compounds combined with specific additives
    • C11D3/3937Stabilising agents
    • C11D3/394Organic compounds
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/39Organic or inorganic per-compounds
    • C11D3/3942Inorganic per-compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/22Gas releasing
    • A61K2800/222Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30Characterized by the absence of a particular group of ingredients
    • A61K2800/31Anhydrous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/11Peroxy compounds, peroxides, e.g. hydrogen peroxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/001Preparations for care of the lips

Definitions

  • anhydrous H 2 0 solution is slowly added to the cooled PVP suspension in an anhydrous solvent in an amount corresponding to the desired molar ratio of PVP and H 2 0 2 .
  • a small excess of the H 2 0 2 solution over the desired stoichiometric ratio is used.
  • a PVP-H 0 2 complex with a 1:1 molar ratio
  • about 111 g. PVP and 100 g. of a 42% H 2 0 2 and 300 ml of anhydrous solvent is used, providing a small excess, e.g. about 5%, over the required stoichiometric amount of 34 g. H 2 0 .
  • This excess H 2 0 2 is recoverable from the mother liquor.
  • Example 1 The process of Example 1 was followed using 50 g. of the H 2 0 2 solution in anhydrous ethyl acetate.
  • the resultant complex contained 13.2% H 2 0 2 and 0.5% water.
  • Example 6 The procedure of Example 6 is followed using PVP-CI 160 g.; ethylacetate 450 g.; and 85% H 2 0 2 56 g. 197 g. of a PVP-H 2 0 2 complex with 19.2% H 2 0 2 containing 1.56% H 2 0 is obtained. Further drying at 40-50°C. in vacuo will reduce the water content to 0.5% H 2 0.

Abstract

What is provided herein are substantially anhydrous complexes of PVP and H2O2 in molar ratios of between about 2:1 and 1:1, respectively, which corresponds to between about 13 % and about 23 % by weight H2O2. The complexes of the invention are substantially uniform, free-flowing, fine white powders. The complexes herein are prepared by reacting PVP and H2O2 in substantially the molar ratio predetermined for the complex. In one suitable process for preparing such complexes the reaction is carried out between the reactants in an anhydrous organic solvent such as ethyl acetate. A method is provided herein for reducing the microbial content of surfaces which comprises contacting said surface with a microbiocidal amount of said free-flowing, substantially anhydrous complex of PVP and H2O2.

Description

- 1 -
SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP AND H?Q
This invention relates to substantially anhydrous complexes of polyvinylpyrrolidone (PVP) and hydrogen peroxide (H 02) which are, free-flowing, uniform, fine white powders containing a predetermined amount of H20 therein.
Stabilized H202 compositions have found wide utility in commercial and industrial applications, e.g. as disinfectants, sterilization agents, as bleaching materials, washing concentrates, etchants, in cosmetic preparations, as clarification agents for alcoholic and fermented beverages, and as a catalyst in polymerizations requiring a free radical source. In biological applications which require a disinfectant or sterilization agent, such H20 compositions require release of an effective amount of oxygen at a controlled rate without storage decomposition caused by interaction with organic matter, light and/or heat.
Shiraeff, in U.S. Patents 3,376,110 and 3,480,557, discloses a solid, stabilized hydrogen peroxide composition of hydrogen peroxide and a polymeric N-vinyl heterocyclic compound prepared in an aqueous solution of the components. These compositions generally were prepared by mixing various weights of PVP and aqueous H202, and evaporating the solution to dryness. The Shiraeff composition, which was believed to be a solid, dry complex, was described as not necessarily anhydrous due to the hydrophilic nature of the PVP and the water present in the reaction solution. Shiraeff further stated that such amounts of water could be tolerated, however, if it did not affect the solid dry characteristics of the complexes. The H202 content of the composition was given as being at least 2%, and preferably 4.5 to 70% by weight. Prolonged drying to remove water from such compositions, however, resulted in loss of H202 forming a brittle, transparent, gummy, amorphous product. In U.S. 3,480,557, the aqueous PVP-H202 complexes, upon heating to dryness, produced hard, brittle chips which had a variable
H202 content ranging from about 3.20 to 18.07% by weight, depending upon the drying times.
In accordance with the invention, substantially anhydrous PVP-H202 complexes are provided having a predetermined molar ratio of PVP to H 02 ranging from between about 2:1 to about 1:1, corresponding to a H202 content of about 13% to about 23%. The substantially anhydrous PVP-H202 complexes are prepared by reaction of PVP and H202 in a substantially anhydrous organic solvent and are obtained by filtration of the suspension as a uniform, free-flowing, fine white powder.
The PVP polymeric starting material used in the present invention is available commercially as a solid of varying molecular weight, water solubility and water content. A typical PVP polymer is water soluble PVP-K30 (GAF Corp.) which contains less than 5% water. Other PVP polymers of different molecular weight, water solubility and water content also may be used, as for example, K-90 and K-120; Polyclar AT; Crospovidone; and the like. Both water soluble and water insoluble PVP polymers may be used.
In this process, the PVP powder is suspended in a suitable anhydrous organic solvent, such as a carboxylie acid ester, an alkyl ether, e.g. t-butyl methyl ether, or a hydrocarbon, e.g. cyclohexane. Preferably, however, an alkyl or cycloalkyl ester of a saturated aliphatic carboxylic acid is used, as for example, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate and ethyl propionate. The PVP suspension in ethyl acetate, for example, then is cooled, preferably to about 0°C. , at which temperature precipitation of the desired complex as a fine powder may suitably occur. An anhydrous H202 solution in an anhydrous organic solvent, preferably the same carboxylic acid ester used to form the PVP suspension, then is prepared according to the process of U.S. 4,564,514. In this step, an aqueous H202 solution (e.g. a 50% solution) is treated with the ester and then subjected to azeotropic distillation at a predetermined low pressure, e.g. at 200 mm Hg and 55βC. The resultant product is an anhydrous H202 solution in the ester having a H202 concentration in the range of about 20 to 50% H202.
Thereafter the thus-prepared anhydrous H20 solution is slowly added to the cooled PVP suspension in an anhydrous solvent in an amount corresponding to the desired molar ratio of PVP and H202. Preferably, however, a small excess of the H202 solution over the desired stoichiometric ratio is used. For example, to prepare a PVP-H 02 complex with a 1:1 molar ratio, about 111 g. PVP and 100 g. of a 42% H202 and 300 ml of anhydrous solvent is used, providing a small excess, e.g. about 5%, over the required stoichiometric amount of 34 g. H20 . This excess H202 is recoverable from the mother liquor.
Upon mixing the PVP and H20 , a fine white powder is obtained which is filtered and dried at about 40-50°C. in vacuo to remove residual solvent. The product is a stable, anhydrous complex in the form of a uniform, free-flowing, fine white powder having a H202 content between about 13% (2:1 molar ratio) and 23% H20 (1:1 molar ratio) . iβ water content of the product generally is equal to or less than the amount present in the PVP starting material, and usually is less than 1%, preferably about 0.5%.
An alternative process for preparing the substantially anhydrous complexes of the invention uses a water-insoluble PVP polymeric starting material which is available commercially as a solid of varying molecular weight and water content. A suitable water-insoluble PVP polymer is Crospovidone, sold by GAF Chemicals Corp., which contains about 4% water. These PVP powders preferably are dried at about 105°C. in vacuo for about 2 hours to reduce the water content to less than about 1%.
The dried PVP powders then are suspended at about 5-10°C. under agitation in a substantial quantity of an anhydrous organic solvent, such as a carboxylic acid ester, a dialkyl ether, e.g. t-butyl methyl ether, or a hydrocarbon e.g. hexane or cyclohexane. Preferably an alkyl or cycloalkyl ester of a saturated aliphatic carboxylic acid is used, as for example, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate and ethyl propionate. Ethyl acetate is preferred.
A 70-85% aqueous H202 solution then is added to the cooled PVP suspension under continued agitation during a period of about 30 minutes to about 1 hour. The amounts of PVP starting material and H202 solution used correspond to the desired molar ratio of PVP and H 02 in the complex. Preferably, however, a small excess of the H202 solution over the desired stoichiometric ratio is used. This excess H202 is recoverable from the mother liquor.
Upon mixing the PVP and H20 , a uniform, free-flowing, fine, white powder precipitate is obtained which is filtered and dried at about 40-50°C. in vacuo to remove residual solvent and water. The product is a stable, anhydrous complex in the form of a uniform, free-flowing, fine, white powder having a H202 content between about 18 and 22% H202. The water content of the product generally is about 2% or less, and usually can be dried to less than about 1%.
Continued drying under these low temperature and vacuum conditions reduces the final water content in the complex to a substantially anhydrous powder with no loss of H202. EXAMPLE .1
Preparation of Substantially Anhydrous 1:1 PVP-H2O2 Complex
PVP K-30 (GAF Corp.) (4.5% water). 111 g., was suspended in 200 ml. of anhydrous ethyl acetate (0.01% H20) , and the suspension was cooled to 0°C. An anhydrous hydrogen peroxide solution in ethyl acetate was prepared by treating 200 g. of 50% aqueous hydrogen peroxide with 6 1. of ethyl acetate and azeotroping in a rotary evaporator to remove 100 g. of water. A 42.7% H202 solution in anhydrous ethyl acetate was obtained. Then 100 g. of this solution was added slowly over a period of about 1-1/2 hours to the PVP suspension. A fine white precipitate formed which was filtered and dried in vacuo. The resultant water soluble complex contained 23.4% by weight H202 and 0.5% by weight water, upon drying at 50βC. in vacuo for 2 hours.
EXAMPLE 2
Preparation of Anhydrous 2:1 PVP-H2O Complex
The process of Example 1 was followed using 50 g. of the H202 solution in anhydrous ethyl acetate. The resultant complex contained 13.2% H202 and 0.5% water.
EXAMPLE 3
200 g. of PVP-CI (K-30) was suspended in 300 g. of anhydrous ethyl acetate. Then H202, 424 g., 19.6% H 02 and 0.84% H 0 was added slowly to the cooled (5βC.) suspension of PVP/ethyl acetate. The addition required 45 minutes. The suspension then was stirred for another 45 minutes, filtered, and washed with anhydrous ethyl acetate. The fine powder was dried at 40-50°C. for 2 hours under vacuum to recover ethyl acetate. The yield was
258.8 g. of water soluble PVP-H 02 containing 23.1%
H202 and 0.4% H20 as a free flowing white powder.
The mother liquor of ethyl acetate, 485 g. contained 4.51%
H202-
EXAMPLE 4
35 g. of crospovidone was suspended in 100 ml. of anhydrous ethyl acetate. Then H202, 27.5 g. as a 42.7% H202 solution was added with cooling at 5-10βC. The mixture was stirred for l hour. The precipitated complex was filtered to provide 46.1 g. of a water insoluble PVP-H 02 complex containing 24.9% H202, after drying at 40-50°C. for 2 hours.
COMPARATIVE EXAMPLE
Preparation of Aqueous PVP-H2O Complex According to U.S. 3,480,557
6 g. of PVP-CI (K-30) (GAF Corp.) (4.5% water) was dissolved in 50 ml. of methanol. Then 7 g. of a solution of H202 in water (50%) was added, followed by heating at 45βC. for 2 hours, and evaporation of methanol for 12 hours. A gummy, amorphous residue was obtained which contained 12.92% H202 and 5% H 0. EXAMPLE 5
Stability of Anhydrous Complex of Example 1
After 43 days at 60°C. the complex lost only 15% of its H202 activity, which shows excellent stability toward decomposition. At room temperature, decomposition was only 1.5% after 60 days.
EXAMPLE 6
Preparation of Free-Flowing, Fine, White Powders of PVP-H2O2 Complex
PVP-CI (K-30) (GAF Corporation) (4.5% water) was dried at 105°C. in vacuo for 2 hours until it contained only 1.1% water. 160 g. of the dried, water-insoluble PVP was suspended in 450 g. of anhydrous ethyl acetate (0.01% water) , and the suspension was cooled to 5°-10°C. while agitating the suspension. Then 55 ml. of 70% hydrogen peroxide solution in water (71 g. H20 ) was added slowly over a period of 35 minutes to the agitated suspension keeping the temperature at 5°-10°C. A fine, white precipitate was formed which was filtered to yield 312 g. of a wet product which was dried at 40°-50°C. in vacuo for 4 hours. 200 g. of a free-flowing fine, white powder was obtained which contained 19.5% H 02 and 2.9% water. Further drying under the same conditions for an additional 6 hours reduced the water content to 0.5% while maintaining the H202 content at 18.5% and without affecting the physical properties of the powder.
In the drying step above, 77.9 g. of mostly ethyl acetate was collected in the vacuum trap which also contained 0.2% H202 and 3.78% water in the upper layer and 8.0 g. of mostly water (92%) with 0.63% H202. The filtrate (363 g.) obtained above contained 2.75% H202 and 1.54% H20, the rest being ethyl acetate, which was recycled as described in Example 2 below.
EXAMPLE 7
The procedure of Example 6 is followed using PVP-CI 160 g.; ethylacetate 450 g.; and 85% H202 56 g. 197 g. of a PVP-H202 complex with 19.2% H202 containing 1.56% H20 is obtained. Further drying at 40-50°C. in vacuo will reduce the water content to 0.5% H20.
EXAMPLE 8
Preparation of Free-Flowing, Fine, White Powders of PVP-H O Complex by Recycling the Filtrate of Example 1
To the filtrate from Example 6, 363 g., was added 90 g. of fresh, anhydrous ethyl acetate followed by cooling to 5°-10°C. Then 170 g. of dried PVP-CI was added at once whereupon the exothermic reaction increased the temperature to 12βC. The suspension was cooled to 5°C. with an ice-water bath. Then 58 g. of a 70% H20 solution was added over a period of 2 hours with good agitation, a fine, white precipitate was formed and filtered to provide 320 g. of a wet cake which was dried at 40°-50°C. under vacuo for 4 hours to yield 202 g. of a free-flowing, fine, white powder containing 18.9% H202 and 3.1% H20. Further drying under the same conditions for an additional 6 hours lowered the water content to 0.6%, and the H202 content to 18.3%, without affecting the physical characteristics of the powder. The filtrate weighed 358 g. , and was mostly ethyl acetate with 2.58% H202 and 1.49% water.
COMPARATIVE EXAMPLE 2
Preparation of Aqueous PVP-H 02 Complex according to U.S. 3,480,557
To 6 g. of PVP-CI (K-30) (GAF Corporation) (4.5% water) was dissolved in 50 ml. of methanol was added 7 g. of a solution of H202 in water (50%) , followed by heating at 45βC. for 2 hours, and evaporation of methanol for 12 hours. The gummy, amorphous residue contained 12.92% H202 and 5% H20.
EXAMPLE 9
Stability of Anhydrous Complex of Example 6
After 43 days at 60°C. the complex lost only 15% of its H202 activity, which shows excellent stability toward decomposition. At room temperature, decomposition was only 1.5% after 60 days.
EXAMPLE 10
Stability of Aqueous Solutions of Anhydrous Complex of Example 6
An aqueous solution of the complex of Example 6 containing 3.75% H20 was heated at 58°C. for 96 hours. At the end of this period, the solution analyzed for 2.75% H20, which indicated excellent stability for aqueous solutions of the complex of the invention. COMPARATIVE EXAMPLE 3
Stability of Aqueous Solutions of (a) Urea/H2 Q 2 and (b) HQOQ
(a) Under the same conditions as in Example 10, a urea/H 02 solution, after only 36 hours, was reduced in H202 content from 3.5% to 0.6% H202. (b) An H202 solution itself lost all of its 3.0% H202 content after 36 hours.
Antimicrobial formulations of the complexes of the invention are prepared using a microbiocidal amount of the substantially anhydrous PVP-H202 complex, and an acceptable diluent and/or other active and inactive ingredients in the form of a suspension, solution, dispersion gel, powder, paste, suppository, aerosol, ointment, tablet, etc. The formulation may also be impregnated into or applied onto a suitable support, such as a gauze, cotton swab, sponge, etc. Generally, the complex will be activated by water present on the surface containing the microbes, the water functioning to release the active H202 from the complex.
- 11 -
FORMULATION 1
Figure imgf000013_0001
The suppository dissolves completely in about 1 ml of water in about 10 minutes at a temperature of about 37βC. Upon contact with water, a slight development of foam starts with simultaneous dissolution of the suppository. The foam development increases constantly until the dissolution is complete. The foam which forms has fine pores, is even and remains as such over an extended period of time. The nonoxynol-9 is a spermaticide, and the amphoteric-19 and PVP-peroxide are microbiocides.
FORMULATION 2
EFFERVESCENT MOUTHWASH TABLET
Ingredient Percent Wt. (grams)
Anhydrous PVP-H202
(23.1%) (Ex.l) Sodium bicarbonate (granular) Sodium carbonate, anhydrous Citric acid, anhydrous (granular) Aminoacetic acid Flavorants (spray dried) Color
Sodium benzoate (fine powder)
Figure imgf000014_0001
100% 447 mg.
The tablets are compressed with 3/4-in. diameter, flat-faced, bevel-edge tooling. The tablet ingredients, other than the anhydrous PVP-peroxide complex, are mixed, lightly dampened, and granulated. To the slightly dampened granules the anhydrous PVP-peroxide complex is added, and the well-mixed, slightly-moist ingredients are compressed, then immediately thereafter placed in a 70°C. forced draft oven for 1 hour to drive off any residual water. The cooled tablets are immediately packaged in air tight aluminum foil pouches.
The tablets are added to 60 cc (2 oz.) of water for use as an effervescent mouthwash and gargle. FORMULATION 3
NON-AQUEOUS OINTMENT
Ingredient Percent wt.(g.) Anhydrous PVP-H202 15 150
(23%) (Ex.l) Sorbitan Monopalmitate 10
(Span* 40-Atlas) Polyethylene Glycol 400 14 140
Monostearate Polyethylene Glycol 400 35 350 Polyethylene Glycol 4,000 35 350
100% 1,000 g.
The polyethylene glycols and the sorbitan monopalmitate are warmed on a water bath to 70βC. and the complex is added to the well-stirred molten mass. Stirring is continued until the ointment is well-solidified.
FORMULATION 4
ANTIBACTERIAL LIPSTICK
Figure imgf000015_0001
100% 2.00 g.
The formulation is prepared as in 3 above. - 14 -
FORMULATION 5
POLYETHYLENE GLYCOL-CONTAINING OINTMENT
Ingredient Anhydrous PVP-H202
(23%) (Ex. 1) Sodium Carbonate Polyethylene Glycol 4000 Polyethylene Glycol 400
Figure imgf000016_0001
Heat the polyethylene glycol 4000 and 400 with constant stirring on a water bath at 65°C. Slowly add the micronized anhydrous sodium carbonate and PVP-H202 complex with constant stirring. Cool until the mass is well mixed and congealed.
FORMULATION 6
Figure imgf000017_0001
100.0%
All D items in formula above should be micropulverized and blended. Sprinkle the xanthum gum into glycerin with constant agitation until uniform (Phase A) . Add the polyethylene glycol 400 (Phase B) to Phase A with continued agitation. Sprinkle in Povidone K-90 until uniform and with constant stirring add the well mixed micronized ingredients of Phase D. Seal unit with cover and apply 28 or more inches of vacuum for 30-45 minutes with continuous agitation. Add all ingredients of phase E, starting with the hydrogen peroxide complex (item 1) , under continued agitation and mix until uniform. Mix under vacuum (28 inches or more) for 5 additional minutes. - 16 -
FORMULATION 7
Figure imgf000018_0001
Blend micronized powders of the above two ingredients until homogeneous. Add ethyl alcohol to the well blended powder until a thick homogeneous paste is achieved. Lay a homogeneous layer of 700 mg plus the ethyl alcohol used for dispersion on 1 sq. inch of bandage. Place the coated bandage material under vacuum and heat until the ethyl alcohol is completely evaporated. The resultant mixture of the H202 complex and povidone K-90, evenly spread on 1 square inch of bandage will yield about 3% of available H 02 from the solid povidone mixture. If substantive icrobicide activity is desired, 0.1% of cetyl pyridinium chloride can be mixed into the above blend before evaporation of the ethyl alcohol.
FORMULATION 9
EAR DROPS SOLUTION
Ingredient Percent Wt. (q.) Anhydrous PVP-H202 6.5 6.5 (23%) (Ex. 1) Anhydrous glycerol 93.5 93.5 100% 100g.
FORMULATION 10
SOFT LENS DISINFECTION TABLET
Ingredient Anhydrous PVP-H202
(23%) (Ex. 1) Sodium bicarbonate (granular) Sodium carbonate, anhydrous Citric acid, anhydrous granular Sodium benzoate (fine powder)
Figure imgf000019_0001
100% 1.84 g.
The tablet ingredients, other than the anhydrous PVP-H202 and sodium benzoate are mixed, lightly dampened to form a damp granule. To the slightly dampened granules the povidone peroxide and sodium benzoate are added so that granules with a damp feel are compressed using 1-1/4" flat-faced, bevel-edge punches. Immediately after compression the damp tablets are placed in a 70°C. forced draft oven for 1 hour to drive off any residual water. The cooled tablets are immediately packaged in air-tight aluminum foil pouches.
FORMULATION 11
Figure imgf000020_0001
H202 Activity 3% 3.5% 5.0%
The above powders were mixed together to provide the desired composition.
FORMULATION 12
WOUND DRESSING
Ingredient Anhydrous PVP-H202
(22.8% H202) Absolute Ethanol
Figure imgf000020_0002
A 1% H202 solution of the above composition is applied to a wound. A film is formed which is effective to disinfect the wound.
FORMULATION 13
COLD WATER LAUNDRY TABLET
Ingredient Percent Wt. (g.)
PVP-H202 (23%) (EX. 1) 81.5 1.50
Sodium benzoate (fine powder) 1.64 0.03
100% 1.84 g.
These anhydrous PVP-H202 tablets are an effective cold water bleach-disinfectant for cleaning clothes, etc. In use, the PVP portion of the complex can chelate with inorganic ions (e.g. Ca++, Mg++) in the water to reduce water hardness. It can also provide laundry detergents with the properties of antiredeposition or suspension of dirt, anti-dye transfer, along with its bleaching and disinfectant action.
FORMULATION 14
WATER DISINFECTANT TABLET
Ingredient Sodium bicarbonate Sodium carbonate, anhydrous Citric Acid, anhydrous granules Povidone-H202 (20%) Sodium benzoate (fine powder)
Figure imgf000021_0001
100.0% 1.59 g. This tablet should be dissolved in one quart of water and allowed to remain for 5 minutes after the tablet is dissolved before the water is ready to drink. To prepare the tablet, follow the same directions as given in Formulation 10 except use a 1 inch flat-faced, bevel-edge punch.
The above formulations and applications illustrate methods of reducing the bacterial content of surfaces using the anhydrous PVP-H202 complex of the invention.

Claims

WHAT IS CLAIMED IS:
1. A stable complex of PVP and H202 in a molar ratio of between about 2:1 and about 1:1, respectively, which is obtained as a uniform free-flowing, fine, white powder by direct reaction between suspended PVP and H202 in substantially the molar ratio predetermined for the complex.
2. A complex according to claim 1 wherein the complex contains essentially little or no water or free hydrogen peroxide therein.
3. A process of preparing a stable, uniform free-flowing powder complex of PVP and H202 which comprising suspending PVP powders in an anhydrous medium and reacting H 02 therewith.
4. A process according to claim 2 wherein the H202 is reacted in substantially the same molar ratio as desired in the complex.
5. A process according to claim 3 in which PVP is suspended in anhydrous ethyl acetate.
6. A suspension process for preparing uniform, free-flowing fine, white powders of a substantially anhydrous complex of PVP and H 02 having an H20 content between about 18 and about 22% H 0 which comprises:
(a) forming a suspension of water-insoluble PVP containing less than about 1% water in an anhydrous organic solvent,
(b) slowly adding a predetermined amount relative to the PVP of an aqueous H202 solution containing about
70 to about 85% by weight H202, at a temperature of about 0β-10°C. under agitation to precipitate a PVP-H202 complex in the form of a uniform, free-flowing, fine, white powder,
(c) filtering, and
(d) drying the wet precipitate to form the desired powders.
7. A suspension process according to claim 6 wherein said organic solvent is anhydrous ethyl acetate.
8. A process according to claim 6 wherein the filtrate is recycled for use in step (a) .
9. A process according to claim 6 wherein drying is carried out at about 50°-60βC. in vacuo.
10. A method for reducing the microbial content of surfaces which comprises contacting said surface with a microbiocidal amount of a substantially anhydrous complex of PVP and H202 in the form of a free-flowing powder having an H202 content of about 3 to 24% by weight, wherein said complex is present in a formulation in an amount of about 0.1 to 15% by weight.
11. A method according to claim 10 wherein said complex is present on a support.
12. A method according to claim 11 wherein said support is a gauze, cotton swab or sponge.
13. A method according to claim 10 wherein said complex is present in a non-aqueous formulation.
14. A method according to claim 10 wherein said surface comes into contact with living tissue.
15. A formulation for reducing the microbial content of surfaces which include a microbiocidal amount of an anhydrous PVP and H20 complex, having an H202 content of about 3 to 24% by weight.
16. A method according to claim 1 further characterized in that said surface is contacted in the presence of water.
17. A formulation according to claim 16 wherein the complex has a molar ratio of PVP and H202 between about 2:1 and about 1:1.
18. A formulation according to claim 16 which also includes one or more of an acceptable diluent, and an active or inactive ingredient.
19. A formulation according to claim 16 which is in the form of a suspension, solution, suppository, gel, powder, paste, ointment, or tablet, optionally, on a support.
20. A formulation according to claim 16 which is a non-aqueous composition.
21. A formulation according to claim 16 which is a vaginal suppository, an effervescent mouthwash, a non-aqueous ointment, a polyethylene glycol-containing ointment, an anhydrous toothpaste, a tooth powder, a medicated bandage, an ear drop solution, a soft lens disinfectant tablet, a medicated powder, a wound dressing, a cold water laundry tablet, or a water disinfectant tablet.
PCT/US1990/005846 1989-11-08 1990-10-15 SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP and H2O¿2? WO1991007184A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US434,943 1989-11-08
US07/434,943 US5008093A (en) 1989-11-08 1989-11-08 Anhydrous complexes of PVP and hydrogen peroxide
US450,695 1989-12-14
US07/450,695 US5008106A (en) 1989-12-14 1989-12-14 Method for reducing the microbial content of surfaces with a microbiocidal, anhydrous complex of PVP-H2 O2
US07/533,749 US5066488A (en) 1988-12-01 1990-06-06 Semi-anhydrous, suspension process for preparing uniform, free-flowing, fine, white powders of substantially anhydrous complexes of PVP and H2 O2 containing about 18 to about 22% H2 O2
US533,749 1990-06-06

Publications (1)

Publication Number Publication Date
WO1991007184A1 true WO1991007184A1 (en) 1991-05-30

Family

ID=27411865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/005846 WO1991007184A1 (en) 1989-11-08 1990-10-15 SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP and H2O¿2?

Country Status (2)

Country Link
CA (1) CA2028354A1 (en)
WO (1) WO1991007184A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605690A1 (en) * 1992-06-29 1994-07-13 Edward Shanbrom Povidone hydrogen peroxide preservation of blood, tissues and biological fluids
WO1994015648A1 (en) * 1992-12-30 1994-07-21 Bausch & Lomb Incorporated Treating of contact lenses with compositions comprising pvp-h2o¿2?
WO1997020867A1 (en) * 1995-12-05 1997-06-12 Basf Aktiengesellschaft Powdery complexes of hydrogen peroxide and polymers
EP0832846A2 (en) * 1996-09-30 1998-04-01 Basf Aktiengesellschaft Complexes of polymer and hydrogen peroxide
WO1998014199A1 (en) * 1996-09-30 1998-04-09 Basf Aktiengesellschaft Topical products as prophylactic or curative agents for bacterial skin infections
EP1041138A1 (en) * 1999-04-02 2000-10-04 Unilever Plc Household cleaning compositions
US6235318B1 (en) 1999-01-21 2001-05-22 Charles M. Lombardy, Jr. Effervescent chewing gum
WO2003053481A1 (en) * 2001-12-20 2003-07-03 Kimberly-Clark Worldwide, Inc. Products for reducing microbial organic compounds
WO2005018591A1 (en) * 2003-08-15 2005-03-03 Colgate-Palmolive Company Non-aqueous liquid tooth whitening composition
WO2006026424A1 (en) * 2004-08-27 2006-03-09 Colgate-Palmolive Company Oral care composition with cross-linked polymer peroxide
WO2006073822A1 (en) 2004-12-30 2006-07-13 Colgate-Palmolive Company Tooth whitening composition containing cross-linked polymer-peroxides
EP1738802A1 (en) * 2005-06-30 2007-01-03 GC Corporation Pasty dental bleaching material
WO2007037961A1 (en) * 2005-09-27 2007-04-05 Colgate-Palmolive Company Single phase whitening dentifrice
JP2008174521A (en) * 2007-01-22 2008-07-31 Gc Corp Dental composition
US8568695B2 (en) 2006-05-01 2013-10-29 Colgate-Palmolive Company Oral care composition with silicone composite
WO2014149321A1 (en) 2013-03-15 2014-09-25 American Sterilizer Company Reactive surface coating having chemical decontamination and biocidal properties
WO2016093815A1 (en) * 2014-12-10 2016-06-16 Colgate-Palmolive Company Dental floss coating composition
WO2017024110A1 (en) 2015-08-04 2017-02-09 Isp Investments Llc Polymers derived from amino-functional vinyl alcohol ethers and applications thereof
US9974634B2 (en) 2012-12-14 2018-05-22 Colgate-Palmolive Company Methods for whitening teeth
CN111235691A (en) * 2020-02-03 2020-06-05 珠海睿展生物材料有限公司 Nanofiltration antibacterial material, preparation method and application thereof
CN112587500A (en) * 2020-12-10 2021-04-02 武汉纺织大学 Core-shell structure microsphere with oxygen production function and preparation method thereof
US11540996B2 (en) * 2010-12-22 2023-01-03 Colgate-Palmolive Company Oral care compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376110A (en) * 1967-01-30 1968-04-02 Gen Aniline & Film Corp Solid stabilized hydrogen peroxide compositions
US3480557A (en) * 1967-01-30 1969-11-25 Gaf Corp Solid stabilized hydrogen peroxide compositions
US4801460A (en) * 1986-04-11 1989-01-31 Basf Aktiengesellschaft Preparation of solid pharmaceutical forms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376110A (en) * 1967-01-30 1968-04-02 Gen Aniline & Film Corp Solid stabilized hydrogen peroxide compositions
US3480557A (en) * 1967-01-30 1969-11-25 Gaf Corp Solid stabilized hydrogen peroxide compositions
US4801460A (en) * 1986-04-11 1989-01-31 Basf Aktiengesellschaft Preparation of solid pharmaceutical forms

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605690A4 (en) * 1992-06-29 1994-12-07 Edward Shanbrom Povidone hydrogen peroxide preservation of blood, tissues and biological fluids.
EP0605690A1 (en) * 1992-06-29 1994-07-13 Edward Shanbrom Povidone hydrogen peroxide preservation of blood, tissues and biological fluids
WO1994015648A1 (en) * 1992-12-30 1994-07-21 Bausch & Lomb Incorporated Treating of contact lenses with compositions comprising pvp-h2o¿2?
WO1997020867A1 (en) * 1995-12-05 1997-06-12 Basf Aktiengesellschaft Powdery complexes of hydrogen peroxide and polymers
EP0832846A2 (en) * 1996-09-30 1998-04-01 Basf Aktiengesellschaft Complexes of polymer and hydrogen peroxide
WO1998014199A1 (en) * 1996-09-30 1998-04-09 Basf Aktiengesellschaft Topical products as prophylactic or curative agents for bacterial skin infections
EP0832846A3 (en) * 1996-09-30 1998-07-08 Basf Aktiengesellschaft Complexes of polymer and hydrogen peroxide
US6235318B1 (en) 1999-01-21 2001-05-22 Charles M. Lombardy, Jr. Effervescent chewing gum
EP1041138A1 (en) * 1999-04-02 2000-10-04 Unilever Plc Household cleaning compositions
US7235263B2 (en) 2001-12-20 2007-06-26 Kimberly-Clark Worldwide, Inc. Processes for controlling microbial organic compound production
WO2003053481A1 (en) * 2001-12-20 2003-07-03 Kimberly-Clark Worldwide, Inc. Products for reducing microbial organic compounds
US6887496B2 (en) 2001-12-20 2005-05-03 Kimberly-Clark Worldwide, Inc. Products for controlling microbial organic compound production
AU2004266663B2 (en) * 2003-08-15 2009-03-05 Colgate-Palmolive Company Non-aqueous liquid tooth whitening composition
EP2181693A1 (en) * 2003-08-15 2010-05-05 Colgate-Palmolive Company Non-aqueous liquid tooth whitening composition
WO2005018591A1 (en) * 2003-08-15 2005-03-03 Colgate-Palmolive Company Non-aqueous liquid tooth whitening composition
WO2006026424A1 (en) * 2004-08-27 2006-03-09 Colgate-Palmolive Company Oral care composition with cross-linked polymer peroxide
US10959936B2 (en) 2004-08-27 2021-03-30 Colgate-Palmolive Company Oral care composition with cross-linked polymer peroxide
CN102379826B (en) * 2004-08-27 2015-12-09 高露洁-棕榄公司 There is the oral care composition of cross-linked polymer peroxide
US10758472B2 (en) 2004-08-27 2020-09-01 Colgate-Palmolive Company Oral care composition with cross-linked polymer peroxide
US11596593B2 (en) 2004-08-27 2023-03-07 Colgate-Palmolive Company Oral care composition with cross-linked polymer peroxide
US9895304B2 (en) 2004-08-27 2018-02-20 Colgate-Palmolive Company Oral care composition with cross-linked polymer peroxide
US8540971B2 (en) 2004-08-27 2013-09-24 Colgate-Palmolive Company Oral care composition with cross-linked polymer peroxide
US9517194B2 (en) 2004-08-27 2016-12-13 Colgate-Palmolive Company Oral care composition with cross-linked polymer peroxide
WO2006073822A1 (en) 2004-12-30 2006-07-13 Colgate-Palmolive Company Tooth whitening composition containing cross-linked polymer-peroxides
AU2005323082B2 (en) * 2004-12-30 2009-12-17 Colgate-Palmolive Company Tooth whitening composition containing cross-linked polymer-peroxides
EP1738802A1 (en) * 2005-06-30 2007-01-03 GC Corporation Pasty dental bleaching material
AU2011200174B2 (en) * 2005-09-27 2012-09-06 Colgate-Palmolive Company Single phase whitening dentifrice
WO2007037961A1 (en) * 2005-09-27 2007-04-05 Colgate-Palmolive Company Single phase whitening dentifrice
JP2015212308A (en) * 2005-09-27 2015-11-26 コルゲート・パーモリブ・カンパニーColgate−Palmolive Company Single phase whitening dentifrice
TWI414313B (en) * 2005-09-27 2013-11-11 Colgate Palmolive Co Single phase whitening dentifrice composition and using method thereof
US8591868B2 (en) 2005-09-27 2013-11-26 Colgate-Palmolive Company Single phase whitening dentifrice
JP2009510062A (en) * 2005-09-27 2009-03-12 コルゲート・パーモリブ・カンパニー Single-phase whitening dentifrice
JP2013100339A (en) * 2005-09-27 2013-05-23 Colgate Palmolive Co Single phase whitening dentifrice
US8568695B2 (en) 2006-05-01 2013-10-29 Colgate-Palmolive Company Oral care composition with silicone composite
JP2008174521A (en) * 2007-01-22 2008-07-31 Gc Corp Dental composition
US11540996B2 (en) * 2010-12-22 2023-01-03 Colgate-Palmolive Company Oral care compositions
US9974634B2 (en) 2012-12-14 2018-05-22 Colgate-Palmolive Company Methods for whitening teeth
EP2967031A4 (en) * 2013-03-15 2016-08-17 American Sterilizer Co Reactive surface coating having chemical decontamination and biocidal properties
JP2016520513A (en) * 2013-03-15 2016-07-14 アメリカン ステリライザー カンパニー Reactive surface coating with chemical decontamination performance and biocidal properties
WO2014149321A1 (en) 2013-03-15 2014-09-25 American Sterilizer Company Reactive surface coating having chemical decontamination and biocidal properties
CN106999413A (en) * 2014-12-10 2017-08-01 高露洁-棕榄公司 Dental floss coating composition
US10285924B2 (en) 2014-12-10 2019-05-14 Colgate-Palmolive Company Dental floss coating composition
WO2016093815A1 (en) * 2014-12-10 2016-06-16 Colgate-Palmolive Company Dental floss coating composition
WO2017024110A1 (en) 2015-08-04 2017-02-09 Isp Investments Llc Polymers derived from amino-functional vinyl alcohol ethers and applications thereof
CN111235691A (en) * 2020-02-03 2020-06-05 珠海睿展生物材料有限公司 Nanofiltration antibacterial material, preparation method and application thereof
CN112587500A (en) * 2020-12-10 2021-04-02 武汉纺织大学 Core-shell structure microsphere with oxygen production function and preparation method thereof
CN112587500B (en) * 2020-12-10 2022-08-05 武汉纺织大学 Core-shell structure microsphere with oxygen production function and preparation method thereof

Also Published As

Publication number Publication date
CA2028354A1 (en) 1991-05-09

Similar Documents

Publication Publication Date Title
US5008106A (en) Method for reducing the microbial content of surfaces with a microbiocidal, anhydrous complex of PVP-H2 O2
WO1991007184A1 (en) SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP and H2O¿2?
US5122370A (en) Method for treating acne vulgaris with a composition containing a stable, high purity, substantially anhydrous complex of PVP-H2 O.sub.2
US5008093A (en) Anhydrous complexes of PVP and hydrogen peroxide
US5108742A (en) Anhydrous complexes of PVP and H2 O2
CA2197087C (en) Sustained release, transparent biocidal compositions
US5183901A (en) Urea-hydrogen peroxide-polyvinylpyrrolidone
US3830908A (en) Anti-microbial compositions utilizing allantoin compounds and complexes
WO2018004739A1 (en) Novel rapid-deposition thin-film forming compositions as effective wound care treatment
JP4416844B2 (en) Cross-linked polyvinyl pyrrolidone-iodine composite and method for producing the same
JP2004509907A (en) Stabilized composition having antibacterial activity
JPS63199799A (en) Production of contact lens washing tablet having sterilizing action
WO2001001994A1 (en) Water resistant film-forming antimicrobial skin-preparation
JPH06507638A (en) Stabilized film-forming antimicrobial aqueous composition of hydrogen peroxide
US5206385A (en) Urea-hydrogen peroxide-polyvinylpyrrolidone process
US5312619A (en) Aqueous stable complex of a strongly swellable, moderately crosslinked polyvinylpyrrolidone and hydrogen peroxide
JP3205529B2 (en) Super water absorbent resin composition
US5242985A (en) Aqueous stable complex of a strongly swellable, moderately crosslinked polyvinylpyrrolidone and iodine
US5846564A (en) Effervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection
CA1317547C (en) Anhydrous application form of low molecular alkali huminates
US5209922A (en) Water soluble polymers having antifungal properties
CA1300493C (en) Radiation compatible iodine formulation
JP2002539140A (en) Iodine preparation
US5019380A (en) Novel antimicrobial compositions and process for preparing the same
JPH0417058B2 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE